Open in interactive viewer → charts, metric popovers & call review

MariMed Grew Its Way Into a Smaller Profit

Record revenue, a turned average order value, and an $81 million debt load — the 280E tax bill is the only thing actually getting bigger
MRMD · Earnings Call · 2026-11-12

A record quarter that fits inside the market cap

MariMed reported the largest revenue quarter in its history on November 12 — $44.2 million, up 5.5% sequentially and 8.5% year over year — and the entire company is still valued at $30.3 million. That is 0.2x price-to-revenue, against 73x at the 2018 peak. The stock is up 10.7% over the last 90 trading days, but it sits 15.5% below its August high and 98.6% below its all-time peak of $5.38.

That gap — record operations, distressed multiple — is the whole story of this call. Nothing in the global tape explains it. The market's top movers this quarter are AI data-center sellers and tariff refund beneficiaries; cannabis is nowhere in the global keyword set. MariMed is not riding a wave. It is standing still in a current that is going the other way, and the quarter's job was to prove it can paddle.

Volume up, price down — and the basket finally turns

The most important sentence of the call was a mix disclosure, not a headline number:

Higher shipment volume added $1.4 million sequentially while we lost ground on price, and volume accounted for roughly 86% of our sequential revenue growth. We are moving significantly more product, and that is offsetting lower prices.

Mario Pinho, Chief Financial Officer · 2026-11-12

That is the entire economic model in one sentence: MariMed wins on doors and units, not price. Doors reached 721, up 7% sequentially and 13% year over year, and market share of the house of brands rose 150 basis points across core markets. But the genuinely new item is on the retail side. average order value is now the single most prominent theme in MariMed's language — a real novelty after years of price compression and basket erosion dominating the transcript. Ryan Crandall flagged it deliberately: “We've been battling industry-wide basket compression for several years now, so I'm particularly proud of our team for helping move AOV in the right direction.” — Ryan Crandall, Chief Executive Officer · 2026-11-12 Average order value rose 3% sequentially and 1% year over year, while transactions grew 2% and 7% — the fourth consecutive quarter of year-on-year transaction growth. That combination is what produced real operating leverage: total operating expenses grew $130,000 on $2.3 million of incremental revenue, dropping the expense ratio from 38% of revenue to 36%.

The machinery behind it is repeatable and cheap: the Thrive loyalty program added 31% more members year to date, and the new Thrive app links sign-up to loyalty enrolment — the same customer experience investment the company has been describing for three quarters, finally showing up in the average ticket.

But the margin promise didn't turn

Here is where the record revenue becomes a slightly uncomfortable story. Adjusted gross margin was 40%, flat sequentially but down roughly 140 basis points year over year. Direct materials rose $3.2 million and manufacturing overhead about $450,000, partly depreciation on production equipment; management also flagged high input costs as a persisting headwind. Adjusted EBITDA of $4.7 million was up 18% sequentially but down 9% year over year — on $3.5 million more revenue.

Compare that with what the CFO said on the prior call, when the pressure was framed as temporary: “These levers, I believe, will carry into the second half of the year.” — Mario Pinho, Chief Financial Officer · 2026-08-13 Three months later the levers held the line, they didn't move it. Mario Pinho was unusually honest about the distinction:

Last quarter, I said the pressure we were seeing was transitional and that there was a clear path back to margin expansion. This quarter, we held adjusted gross margin flat. It's not progress until the line turns up, but the operating leverage underneath it is real.

Mario Pinho, Chief Financial Officer · 2026-11-12

The fundamentals confirm the shape rather than the rhetoric. Gross margin sits at 38.7% on a GAAP basis — the low end of a two-year slide from 45%. And the structural reason, per Pinho, is deliberate: at 44% wholesale mix, MariMed carries the heaviest wholesale weighting in the industry, and its two largest states, Massachusetts and Illinois, are the two where compression is worst. That is a strategy, not an accident, but strategies have prices.

280E is the entire delta — and the whole option value

The clearest, most falsifiable claim on the call was about taxes. Nine-month pretax loss narrowed slightly to $3.4 million while the tax provision rose $1.1 million to $7.4 million. Pinho's summary: “The entire increase in our year-to-date net loss is related to the impact of 280E.” — Mario Pinho, Chief Financial Officer · 2026-11-12 That reframes the whole equity. The operating business is roughly flat-to-better; the 280E tax regime is what turns operating income into a $3.5 million quarterly net loss.

Which is why the call spent as much time on Washington and state ballots as on cannabis. Massachusetts voters rejected Question 8 by roughly 75% — Question 8 entering the company's keyword set for the first time — and Jon Levine's read on federal timing was notably less optimistic than three months ago: “We hoped for more clarity of all by the end of the year, but now I believe we need to wait for the dust to settle after last week's midterm.” — Jon Levine, President and Chief Operating Officer · 2026-11-12 Shareholders have already authorized a reverse split contingent on adult-use rescheduling or banking reform, with uplisting to a major U.S. exchange as the prize. That is a capital-markets option, not an operating one — and it is the same option the company has been describing since 2024.

What management quietly stopped selling

The most revealing change is a subtraction. In late 2025, Levine was pitching a product line: “We're looking at going into the hemp beverage business. We feel that, that is something that we can be very successful at.” — Jon Levine, CEO · 2025-11-06 A year later, hemp beverage is gone as a growth pillar; hemp now appears only as a regulatory tailwind — a ban in Illinois that might push consumers back into licensed stores. Crandall's version was hedged to the point of dismissal: “I think a lot is in the future here with regard to what's going to happen on the hemp side.” — Ryan Crandall, Chief Executive Officer · 2026-11-12

New York has similarly drifted. In March, Levine expected the processing kitchen "up and running before the end of the year" and revenue "late the year or early in '27." On this call it became the first half of 2027. New York is still the right story — a $4 billion addressable market reached with limited capital — but the timeline slipped a full two quarters, and licensing is now the company's highest-margin channel rather than a headline growth driver. Maine, where Betty's Eddies reached the #2 edible position in under a year, is the proof case: licensing revenue grew 43% sequentially but is still under 1% of consolidated revenue.

What has not changed is the refrain about valuation. Levine again pointed to real estate: “that decision provided us with assets that are worth significantly more than our current market cap.” — Jon Levine, President and Chief Operating Officer · 2026-11-12 current market cap has surfaced in MariMed's language in quarter after quarter — it is a genuine asset-backed argument, and also a tell that management has no operating lever left large enough to close the gap on its own.

The balance sheet is the story, in both directions

Cash of $10.4 million is the strongest in more than two years, up $1.9 million sequentially; debt fell to $81.2 million and leverage improved to roughly 4.4x from 5.2x. Free cash flow was positive. But liabilities at 74.6% of assets, up 10.4 percentage points year over year, and effective net cash of negative $70 million describe the same company from the other side. At 0.2x sales, the equity is an option on federal reform and on internalization — selling more of its own brands in its own stores, currently only about a third — not a compounder yet.

The quarter earned its record. It did not yet earn a re-rating.